E Scarr

Summary

Affiliation: Mental Health Research Institute
Country: Australia

Publications

  1. ncbi request reprint Decreased phorbol ester binding in the parahippocampal gyrus from subjects with schizophrenia is not associated with changes in protein kinase C
    E Scarr
    Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Mol Psychiatry 7:683-8. 2002
  2. doi request reprint Muscarinic receptors in psychiatric disorders - can we mimic 'health'?
    E Scarr
    Centre for Neuroscience, The University of Melbourne, and Rebecca L Cooper Research Laboratories, Mental Health Research Institute, Parkville, Vic, Australia
    Neurosignals 17:298-310. 2009
  3. ncbi request reprint A proposed pathological model in the hippocampus of subjects with schizophrenia
    E Scarr
    Rebecca L Cooper Research Laboratories, Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Parkville, Australia
    Clin Exp Pharmacol Physiol 28:70-3. 2001
  4. doi request reprint Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia
    E Scarr
    Centre for Neuroscience, The University of Melbourne, Parkville, Vic, Australia
    Mol Psychiatry 14:1017-23. 2009
  5. ncbi request reprint Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Victoria, Australia
    Life Sci 69:1257-68. 2001
  6. ncbi request reprint Treating schizophrenia: novel targets for the cholinergic system
    T T Money
    The Mental Health Research Institute, Parkville, Victoria, Australia
    CNS Neurol Disord Drug Targets 9:241-56. 2010
  7. ncbi request reprint Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder
    E Scarr
    Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Bipolar Disord 8:133-43. 2006
  8. pmc SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia
    M Udawela
    1 The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, Vic, Australia 2 CRC for Mental Health, Carlton South, Vic, Australia
    Transl Psychiatry 5:e615. 2015
  9. doi request reprint Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders
    B Dean
    The Molecular Psychiatry Laboratory, The Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    Mol Psychiatry 18:767-73. 2013
  10. pmc Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA
    E Scarr
    Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
    Transl Psychiatry 3:e230. 2013

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Decreased phorbol ester binding in the parahippocampal gyrus from subjects with schizophrenia is not associated with changes in protein kinase C
    E Scarr
    Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Mol Psychiatry 7:683-8. 2002
    ..These results suggest that there are changes in molecules capable of binding [(3)H]phorbol 12,13-dibutyrate, other than protein kinase C, in the parahippocampal gyrus from subjects with schizophrenia...
  2. doi request reprint Muscarinic receptors in psychiatric disorders - can we mimic 'health'?
    E Scarr
    Centre for Neuroscience, The University of Melbourne, and Rebecca L Cooper Research Laboratories, Mental Health Research Institute, Parkville, Vic, Australia
    Neurosignals 17:298-310. 2009
    ....
  3. ncbi request reprint A proposed pathological model in the hippocampus of subjects with schizophrenia
    E Scarr
    Rebecca L Cooper Research Laboratories, Division of Molecular Schizophrenia, The Mental Health Research Institute of Victoria, Parkville, Australia
    Clin Exp Pharmacol Physiol 28:70-3. 2001
    ..The model we propose allows us to construct further studies that will test the consequences of such a hyperserotonergic state in the hippocampal formation. This model has the potential to open new avenues in schizophrenia research...
  4. doi request reprint Decreased cortical muscarinic receptors define a subgroup of subjects with schizophrenia
    E Scarr
    Centre for Neuroscience, The University of Melbourne, Parkville, Vic, Australia
    Mol Psychiatry 14:1017-23. 2009
    ....
  5. ncbi request reprint Extended treatment with typical and atypical antipsychotic drugs differential effects on the densities of dopamine D2-like and GABAA receptors in rat striatum
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute, Parkville, Victoria, Australia
    Life Sci 69:1257-68. 2001
    ..The extent to which such changes are involved in the therapeutic effects of drugs such as olanzapine and clozapine remains to be determined...
  6. ncbi request reprint Treating schizophrenia: novel targets for the cholinergic system
    T T Money
    The Mental Health Research Institute, Parkville, Victoria, Australia
    CNS Neurol Disord Drug Targets 9:241-56. 2010
    ....
  7. ncbi request reprint Increased levels of SNAP-25 and synaptophysin in the dorsolateral prefrontal cortex in bipolar I disorder
    E Scarr
    Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Bipolar Disord 8:133-43. 2006
    ....
  8. pmc SELENBP1 expression in the prefrontal cortex of subjects with schizophrenia
    M Udawela
    1 The Florey Institute of Neuroscience and Mental Health, Howard Florey Laboratories, The University of Melbourne, Parkville, Vic, Australia 2 CRC for Mental Health, Carlton South, Vic, Australia
    Transl Psychiatry 5:e615. 2015
    ..24). Our data show that elevated SELENBP1 transcript expression is widespread throughout the prefrontal cortex in schizophrenia, and confirm that this change is a consistent feature of schizophrenia and not a simple drug effect...
  9. doi request reprint Different changes in cortical tumor necrosis factor-α-related pathways in schizophrenia and mood disorders
    B Dean
    The Molecular Psychiatry Laboratory, The Mental Health Research Institute, The University of Melbourne, Parkville, Vic, Australia
    Mol Psychiatry 18:767-73. 2013
    ..Our data suggest there are differential changes in TNFα-related markers in the cortex of people with MDD, BD and Sz that may not be related to classical inflammation and may cause changes in different TNFα-related signaling pathways. ..
  10. pmc Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA
    E Scarr
    Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia
    Transl Psychiatry 3:e230. 2013
    ..These latter data continue to support the hypothesis that microRNAs (miRNA) have a role in the underlying neurobiology of Sz but argue they are differentially affected in subsets of people within that syndrome...
  11. pmc Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects
    A S Gibbons
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    J Affect Disord 116:184-91. 2009
    ..However, there is conflicting evidence regarding the association between individual muscarinic receptors and the two disorders...
  12. ncbi request reprint Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: differential regional changes in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratory, The Mental Health Research Institute of Victoria, Parkville, Victoria 3052, Australia
    Life Sci 74:3115-31. 2004
    ..Since dopamine D(3) receptors are absent or present at low concentrations in the pituitary, our data would suggest the dopamine D(2) receptor is decreased in that tissue from schizophrenic subjects...
  13. ncbi request reprint Antipsychotic drugs: evolving mechanisms of action with improved therapeutic benefits
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, and Department of Pathology, University of Melbourne, Parkville, Victoria, Australia
    Curr Drug Targets CNS Neurol Disord 3:217-25. 2004
    ..It is, therefore, timely to review the evolving nature of the mechanisms of action of different antipsychotic drugs...
  14. ncbi request reprint Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder
    E Scarr
    Rebecca L Cooper Research Laboratories, Mental Health Research Institute, Parkville, Victoria, Australia
    Bipolar Disord 5:257-64. 2003
    ..The purpose of this study was to determine whether there are changes in the density of ionotropic glutamate receptors in the hippocampus of subjects with bipolar disorder...
  15. ncbi request reprint Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Locked Bag 11, Parkville, Victoria 3052, Australia
    Neuroscience 103:9-15. 2001
    ..By contrast, changes in the density of cannabinoid-1 receptors may occur in the caudate-putamen in response to cannabis ingestion...
  16. ncbi request reprint Muscarinic receptors in schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Curr Mol Med 3:419-26. 2003
    ..This review presents data from diverse areas of research to argue that it is now imperative that the therapeutic potential of manipulating the activity of muscarinic receptors for the treatment of schizophrenia is fully explored...
  17. doi request reprint Changed gene expression in subjects with schizophrenia and low cortical muscarinic M1 receptors predicts disrupted upstream pathways interacting with that receptor
    E Scarr
    Molecular Psychiatry Laboratory, Florey Institute for Neuroscience and Mental Health, Parkville, Vic, Australia
    Mol Psychiatry . 2016
    ..Molecular Psychiatry advance online publication, 1 November 2016; doi:10.1038/mp.2016.195...
  18. doi request reprint Evidence for impaired glucose metabolism in the striatum, obtained postmortem, from some subjects with schizophrenia
    B Dean
    The Molecular Psychiatry Laboratory, The Florey Institute for Neuroscience and Mental Health, Parkville, Vic, Australia
    Transl Psychiatry 6:e949. 2016
    ....
  19. ncbi request reprint Possible involvement of muscarinic receptors in psychiatric disorders: a focus on schizophrenia and mood disorders
    B Dean
    Molecular Psychiatry Laboratory, The Florey Institute for Neuroscience and Mental Health, 30 Royal Parade, Parkville, Victoria 3052, Australia
    Curr Mol Med 15:253-64. 2015
    ..Finally, there will be comments on the potential advantages and problems in targeting CHRM1 and CHRM4 to treat the symptoms of schizophrenia and CHRM2 to treat the symptom of depression...
  20. ncbi request reprint Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia
    B Dean
    The Rebecca L Cooper Research Laboratories, The Mental Health Research Institute of Victoria, Parkville, Victoria, Australia
    Mol Psychiatry 7:1083-91. 2002
    ..01) with schizophrenia but M4R mRNA was only decreased in BA 40 (48 +/- 6.6 vs 89 +/- 9.9, P < 0.005). These data suggest that the M1R, at least in the dorsolateral prefrontal cortex, may have a role in the pathology of schizophrenia...
  21. ncbi request reprint Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder
    E A Thomas
    Department of Molecular Biology, The Scripps Research Institute, 10550 Torrey Pines Road, La Jolla, CA, USA
    Mol Psychiatry 8:167-75. 2003
    ..7%). These data demonstrate that there is anatomical overlap in the pathophysiologies of schizophrenia and bipolar disorder, as well as areas of pathology that distinguish the two disorders...
  22. ncbi request reprint Phospholipase C-beta1 knockout mice exhibit endophenotypes modeling schizophrenia which are rescued by environmental enrichment and clozapine administration
    C E McOmish
    Howard Florey Institute, University of Melbourne, Melbourne, Vic, Australia
    Mol Psychiatry 13:661-72. 2008
    ..Thus we have demonstrated a novel mouse model, displaying disruption of multiple postsynaptic signals implicated in the pathogenesis of schizophrenia, a relevant behavioral phenotype and associated gene-environment interactions...